A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Clinical trial NCT00298038 · COMPLETED

Trial details

NCT number: NCT00298038
Sponsor: Bausch Health Americas, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatic Encephalopathy

Start date: 2005-12-19
Primary completion: 2008-08-15
Enrollment: 299

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.